Pelthos Therapeutics (PTHS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $20.15, -0.54% vs the prior close of $20.26.
- Volume 74.39K shares, 1.8x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PTHS dips 0.5% to $20.15 on 1.8x normal volume. Closed at $20.15, -0.54% vs the prior close of $20.26. Day range $19.91–$20.57, opened at $20.27.
PTHS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PTHS dips 0.5% to $20.15 on 1.8x normal volume
- Closed at $20.15, -0.54% vs the prior close of $20.26. Day range $19.91–$20.57, opened at $20.27.
- Volume was 74.39K shares, 1.8x its 50-day average of 41.28K — unusually heavy trading.
- Price is -14.4% vs its 50-day average ($23.53) and -18.5% vs its 200-day average ($24.72).
- 52-week range $18.19–$37.50; today's close sits at 10% of that range, 46.3% below the 52-week high.
Oct 15, 2026 — PTHS ends flat (+0.0%) to $20.26
- Closed at $20.26, +0.05% vs the prior close of $20.25. Day range $20.05–$20.92, opened at $20.43.
- Volume was 59.90K shares, 1.5x its 50-day average of 41.28K.
- Price is -14.6% vs its 50-day average ($23.71) and -18.2% vs its 200-day average ($24.75).
- 52-week range $18.19–$37.50; today's close sits at 11% of that range, 46.0% below the 52-week high.
Oct 14, 2026 — PTHS ends flat (-0.2%) to $20.25
- Closed at $20.25, -0.20% vs the prior close of $20.29. Day range $20.14–$20.80, opened at $20.14.
- Volume was 44.50K shares, 1.0x its 50-day average of 43.04K.
- Price is -15.2% vs its 50-day average ($23.88) and -18.3% vs its 200-day average ($24.79).
- 52-week range $18.19–$37.50; today's close sits at 11% of that range, 46.0% below the 52-week high.
Oct 13, 2026 — PTHS jumps 3.9% to $20.29
- Closed at $20.29, +3.94% vs the prior close of $19.52. Day range $19.52–$20.89, opened at $19.52.
- Volume was 51.80K shares, 1.0x its 50-day average of 49.50K.
- Price is -15.5% vs its 50-day average ($24.01) and -18.2% vs its 200-day average ($24.82).
- 52-week range $18.19–$37.50; today's close sits at 11% of that range, 45.9% below the 52-week high.
Oct 12, 2026 — PTHS slides 4.8% to $19.52, 4 down days in a row
- Closed at $19.52, -4.78% vs the prior close of $20.50. Day range $19.52–$20.70, opened at $20.50.
- Volume was 56.70K shares, 1.0x its 50-day average of 54.85K.
- Price is -19.1% vs its 50-day average ($24.14) and -21.4% vs its 200-day average ($24.85).
- 52-week range $18.19–$37.50; today's close sits at 7% of that range, 47.9% below the 52-week high.
- That makes 4 straight losses.
Oct 9, 2026 — PTHS ends flat (+0.0%) to $20.50, 3 down days in a row
- Closed at $20.50, +0.00% vs the prior close of $20.50. Day range $20.50–$21.16, opened at $20.80.
- Volume was 45.00K shares, 0.8x its 50-day average of 57.27K.
- Price is -15.7% vs its 50-day average ($24.32) and -17.6% vs its 200-day average ($24.88).
- 52-week range $18.19–$37.50; today's close sits at 12% of that range, 45.3% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — PTHS dips 2.3% to $20.50
- Closed at $20.50, -2.33% vs the prior close of $20.99. Day range $20.50–$22.95, opened at $21.41.
- Volume was 67.90K shares, 1.2x its 50-day average of 57.36K.
- Price is -16.1% vs its 50-day average ($24.44) and -17.7% vs its 200-day average ($24.91).
- 52-week range $18.19–$37.50; today's close sits at 12% of that range, 45.3% below the 52-week high.
Oct 7, 2026 — PTHS dips 2.3% to $20.99
- Closed at $20.99, -2.28% vs the prior close of $21.48. Day range $20.99–$21.99, opened at $21.43.
- Volume was 17.70K shares, 0.3x its 50-day average of 59.08K — lighter than usual.
- Price is -14.5% vs its 50-day average ($24.54) and -15.8% vs its 200-day average ($24.94).
- 52-week range $18.19–$37.50; today's close sits at 15% of that range, 44.0% below the 52-week high.
Oct 6, 2026 — PTHS jumps 4.8% to $21.48
- Closed at $21.48, +4.78% vs the prior close of $20.50. Day range $20.50–$22.50, opened at $20.51.
- Volume was 42.90K shares, 0.7x its 50-day average of 60.05K.
- Price is -13.0% vs its 50-day average ($24.68) and -13.9% vs its 200-day average ($24.95).
- 52-week range $18.19–$37.50; today's close sits at 17% of that range, 42.7% below the 52-week high.
Oct 5, 2026 — PTHS dips 0.5% to $20.50
- Closed at $20.50, -0.49% vs the prior close of $20.60. Day range $20.50–$21.74, opened at $21.02.
- Volume was 69.60K shares, 1.1x its 50-day average of 62.78K.
- Price is -17.3% vs its 50-day average ($24.80) and -17.8% vs its 200-day average ($24.95).
- 52-week range $18.19–$37.50; today's close sits at 12% of that range, 45.3% below the 52-week high.
Oct 2, 2026 — PTHS rises 1.2% to $20.60
- Closed at $20.60, +1.23% vs the prior close of $20.35. Day range $20.11–$21.18, opened at $20.11.
- Volume was 22.00K shares, 0.4x its 50-day average of 62.78K — lighter than usual.
- Price is -17.3% vs its 50-day average ($24.91) and -17.5% vs its 200-day average ($24.96).
- 52-week range $18.19–$37.50; today's close sits at 12% of that range, 45.1% below the 52-week high.
PTHS latest news & SEC filings
Every SEC filing by or about PTHS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Greenleaf Peter sold 797 shares at $21.17 (≈$16.87K) on Oct 2, 2026; now holds 23,087
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Friedberg Ezra M sold 558 shares at $20.72 (≈$11.56K) on Oct 2, 2026; now holds 80,484
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Pauls Matthew sold 786 shares at $21.00 (≈$16.51K) on Oct 2, 2026; now holds 13,578
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Aug 18, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Aug 18, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 18, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $15.60M (prior year $0)
- Net income: -$23.42M (prior year -$3.45M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$6.62 (prior year -$5.29) (loss widened vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 13, 2026 · Form 10-Q/A — Quarterly report (amended)
Amended quarterly report
Quarter ended Mar 31, 2026:
- Revenue: $10.91M (prior year $0)
- Net income: -$25.07M (prior year -$1.97M) (loss widened vs Mar 31, 2025)
- Diluted EPS: -$7.57 (prior year -$3.21) (loss widened vs Mar 31, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 4.02 — Earlier financial statements should no longer be relied on (non-reliance).
Aug 7, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Friedberg Ezra M sold 534 shares at $26.03 (≈$13.90K) on Jul 2, 2026
- Friedberg Ezra M sold 24 shares at $27.33 (≈$656) on Jul 2, 2026
- Friedberg Ezra M sold 534 shares at $26.03 (≈$13.90K) on Jul 2, 2026
- Friedberg Ezra M sold 24 shares at $27.33 (≈$656) on Jul 2, 2026
- Friedberg Ezra M sold 534 shares at $26.03 (≈$13.90K) on Jul 2, 2026
- Friedberg Ezra M sold 24 shares at $27.33 (≈$656) on Jul 2, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Pauls Matthew sold 94 shares at $27.36 (≈$2.57K) on Jul 2, 2026
- Pauls Matthew sold 692 shares at $26.00 (≈$17.99K) on Jul 2, 2026
- Pauls Matthew sold 94 shares at $27.36 (≈$2.57K) on Jul 2, 2026
- Pauls Matthew sold 692 shares at $26.00 (≈$17.99K) on Jul 2, 2026
- Pauls Matthew sold 94 shares at $27.36 (≈$2.57K) on Jul 2, 2026
- Pauls Matthew sold 692 shares at $26.00 (≈$17.99K) on Jul 2, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Greenleaf Peter sold 712 shares at $26.00 (≈$18.51K) on Jul 2, 2026
- Greenleaf Peter sold 85 shares at $27.27 (≈$2.32K) on Jul 2, 2026
- Greenleaf Peter sold 712 shares at $26.00 (≈$18.51K) on Jul 2, 2026
- Greenleaf Peter sold 85 shares at $27.27 (≈$2.32K) on Jul 2, 2026
- Greenleaf Peter sold 712 shares at $26.00 (≈$18.51K) on Jul 2, 2026
- Greenleaf Peter sold 85 shares at $27.27 (≈$2.32K) on Jul 2, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade PTHS
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 19, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.97% (largest 4.8%).
- Liquidity: about 37.58K shares (≈$757.23K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $20.15 vs a range of $18.19–$37.50 (10% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on Jul 2, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Peter Greenleaf sold 712 shares on Jul 2, 2026.
- Latest filings: 8-K Oct 1, 2026; 10-Q Aug 13, 2026; 8-K Aug 13, 2026.
- Share count: 3.83M shares outstanding (Aug 10, 2026), +25.8% vs a year earlier — notable dilution.
- Listing: NYSE · industry: Biological Products, (No Diagnostic Substances).
PTHS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 20.27 | 20.57 | 19.91 | 20.15 | 74.39K |
| Oct 15, 2026 | 20.43 | 20.92 | 20.05 | 20.26 | 59.90K |
| Oct 14, 2026 | 20.14 | 20.80 | 20.14 | 20.25 | 44.50K |
| Oct 13, 2026 | 19.52 | 20.89 | 19.52 | 20.29 | 51.80K |
| Oct 12, 2026 | 20.50 | 20.70 | 19.52 | 19.52 | 56.70K |
| Oct 9, 2026 | 20.80 | 21.16 | 20.50 | 20.50 | 45.00K |
| Oct 8, 2026 | 21.41 | 22.95 | 20.50 | 20.50 | 67.90K |
| Oct 7, 2026 | 21.43 | 21.99 | 20.99 | 20.99 | 17.70K |
| Oct 6, 2026 | 20.51 | 22.50 | 20.50 | 21.48 | 42.90K |
| Oct 5, 2026 | 21.02 | 21.74 | 20.50 | 20.50 | 69.60K |
| Oct 2, 2026 | 20.11 | 21.18 | 20.11 | 20.60 | 22.00K |
| Oct 1, 2026 | 21.11 | 21.23 | 20.17 | 20.35 | 44.60K |
| Sep 30, 2026 | 21.26 | 21.68 | 21.01 | 21.01 | 5.50K |
| Sep 29, 2026 | 21.20 | 21.69 | 20.92 | 20.92 | 9.40K |
| Sep 28, 2026 | 22.55 | 22.90 | 21.25 | 21.25 | 12.00K |
| Sep 25, 2026 | 22.66 | 22.92 | 22.15 | 22.19 | 14.80K |
| Sep 24, 2026 | 23.37 | 23.95 | 22.30 | 22.40 | 17.40K |
| Sep 23, 2026 | 23.38 | 24.30 | 23.14 | 23.52 | 34.90K |
| Sep 22, 2026 | 22.70 | 23.44 | 22.42 | 23.24 | 43.90K |
| Sep 21, 2026 | 22.52 | 23.70 | 22.46 | 23.15 | 16.70K |
About Pelthos Therapeutics
Pelthos Therapeutics (PTHS) is listed on the NYSE and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in DURHAM, NC. State of incorporation: NV. Fiscal year ends December 31. SEC CIK 1919246.
PTHS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Richard B Baxter | Director | Apr 1, 2026 |
| Todd C Davis | Director | Jun 15, 2026 |
| Andrew J. Einhorn | Director | Dec 29, 2025 |
| Ezra M Friedberg | Director | Jul 7, 2026 |
| Peter Greenleaf | Director | Jul 7, 2026 |
| Pharmaceuticals Inc Ligand | Director | Dec 19, 2025 |
| Richard Malamut | Director | Apr 6, 2026 |
| Matthew Pauls | Director | Jul 7, 2026 |
| Scott M. Plesha | CEO and President | Apr 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Knuettel Ii Francis | CFO, Treas & Secty | May 26, 2026 |
| John M. Gay | Chief Financial Officer | Apr 20, 2026 |
| Scott M. Plesha | CEO and President | Apr 1, 2026 |
| Sai Rangarao | Chief Commercial Officer | Apr 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Peter Greenleaf | Sale | 712 | $26.00 |
| Jul 2, 2026 | Peter Greenleaf | Sale | 85 | $27.27 |
| Jul 2, 2026 | Peter Greenleaf | Sale | 712 | $26.00 |
| Jul 2, 2026 | Peter Greenleaf | Sale | 85 | $27.27 |
| Jul 2, 2026 | Peter Greenleaf | Sale | 712 | $26.00 |
| Jul 2, 2026 | Peter Greenleaf | Sale | 85 | $27.27 |
| Jul 2, 2026 | Peter Greenleaf | Sale | 712 | $26.00 |
| Jul 2, 2026 | Peter Greenleaf | Sale | 85 | $27.27 |
| Jul 2, 2026 | Ezra M Friedberg | Sale | 534 | $26.03 |
| Jul 2, 2026 | Ezra M Friedberg | Sale | 24 | $27.33 |
| Jul 2, 2026 | Ezra M Friedberg | Sale | 534 | $26.03 |
| Jul 2, 2026 | Ezra M Friedberg | Sale | 24 | $27.33 |
| Jul 2, 2026 | Ezra M Friedberg | Sale | 534 | $26.03 |
| Jul 2, 2026 | Ezra M Friedberg | Sale | 24 | $27.33 |
| Jul 2, 2026 | Ezra M Friedberg | Sale | 534 | $26.03 |
PTHS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $16.80M | $-43.32M | -23.04 | $-22.59M |
| Dec 31, 2024 | $0 | $-7.96M | -14.27 | $-5.79M |
| Dec 31, 2023 | — | $-7.38M | -5.78 | $-981.03K |
| Dec 31, 2022 | — | $-2.46M | — | $-1.57M |
Latest balance sheet: total assets $137.36M, total liabilities $138.86M, cash $24.19M (as of Jun 30, 2026).
PTHS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $28.95 |
| May 14, 2026 | 8-K Item 2.02 (results) | $27.69 |
| Mar 19, 2026 | 8-K Item 2.02 (results) | $22.97 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $34.68 |
| Aug 18, 2025 | 8-K Item 2.02 (results) | $21.26 |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PTHS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.